Trials / Completed
CompletedNCT03014089
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The clinical study will assess the safety, tolerability, and immunogenicity of mRNA-1325 in healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mRNA-1325 | Escalating dose levels |
| OTHER | Placebo |
Timeline
- Start date
- 2016-12-21
- Primary completion
- 2019-07-31
- Completion
- 2019-07-31
- First posted
- 2017-01-09
- Last updated
- 2024-08-21
- Results posted
- 2024-06-17
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03014089. Inclusion in this directory is not an endorsement.